Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.

Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variability, and altered diurnal variations of BP and HR (nighttime dipping and morning surge) in patients with systemic hypertension are each associated with increased adverse cardiovascular events. However, there are n...

Full description

Bibliographic Details
Main Authors: Scott J Denardo, Yan Gong, Rhonda M Cooper-DeHoff, Csaba Farsang, Matyas Keltai, László Szirmai, Franz H Messerli, Anthony A Bavry, Eileen M Handberg, Giuseppe Mancia, Carl J Pepine
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4383326?pdf=render
id doaj-254fec39511f480cbfc333de6ab68b58
record_format Article
spelling doaj-254fec39511f480cbfc333de6ab68b582020-11-25T00:23:38ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012272610.1371/journal.pone.0122726Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.Scott J DenardoYan GongRhonda M Cooper-DeHoffCsaba FarsangMatyas KeltaiLászló SzirmaiFranz H MesserliAnthony A BavryEileen M HandbergGiuseppe ManciaCarl J PepineElevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variability, and altered diurnal variations of BP and HR (nighttime dipping and morning surge) in patients with systemic hypertension are each associated with increased adverse cardiovascular events. However, there are no reports on the effect of hypertension treatment on these important hemodynamic parameters in the growing population of hypertensive patients with atherosclerotic coronary artery disease (CAD). This was a pre-specified subgroup analysis of the INternational VErapamil SR-Trandolapril STudy (INVEST), which involved 22,576 clinically stable patients aged ≥ 50 years with hypertension and CAD randomized to either verapamil SR- or atenolol-based hypertension treatment strategies. The subgroup consisted of 117 patients undergoing 24-hour ambulatory monitoring at baseline and after 1 year of treatment. Hourly systolic and diastolic BP (SBP and DBP) decreased after 1 year for both verapamil SR- and atenolol-based treatment strategies compared with baseline (P<0.0001). Atenolol also decreased hourly HR (P<0.0001). Both treatment strategies decreased SBP variability (weighted standard deviation: P = 0.012 and 0.021, respectively). Compared with verapamil SR, atenolol also increased the prevalence of BP and HR nighttime dipping among prior non-dippers (BP: OR = 3.37; 95% CI: 1.26-8.97 P = 0.015; HR: OR = 4.06; 95% CI: 1.35-12.17; P = 0.012) and blunted HR morning surge (+2.8 vs. +4.5 beats/min/hr; P = 0.019). Both verapamil SR- and especially atenolol-based strategies resulted in favorable changes in ambulatory monitoring parameters that have been previously associated with increased adverse cardiovascular events.http://europepmc.org/articles/PMC4383326?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Scott J Denardo
Yan Gong
Rhonda M Cooper-DeHoff
Csaba Farsang
Matyas Keltai
László Szirmai
Franz H Messerli
Anthony A Bavry
Eileen M Handberg
Giuseppe Mancia
Carl J Pepine
spellingShingle Scott J Denardo
Yan Gong
Rhonda M Cooper-DeHoff
Csaba Farsang
Matyas Keltai
László Szirmai
Franz H Messerli
Anthony A Bavry
Eileen M Handberg
Giuseppe Mancia
Carl J Pepine
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
PLoS ONE
author_facet Scott J Denardo
Yan Gong
Rhonda M Cooper-DeHoff
Csaba Farsang
Matyas Keltai
László Szirmai
Franz H Messerli
Anthony A Bavry
Eileen M Handberg
Giuseppe Mancia
Carl J Pepine
author_sort Scott J Denardo
title Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
title_short Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
title_full Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
title_fullStr Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
title_full_unstemmed Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
title_sort effects of verapamil sr and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil sr-trandolapril ambulatory monitoring substudy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variability, and altered diurnal variations of BP and HR (nighttime dipping and morning surge) in patients with systemic hypertension are each associated with increased adverse cardiovascular events. However, there are no reports on the effect of hypertension treatment on these important hemodynamic parameters in the growing population of hypertensive patients with atherosclerotic coronary artery disease (CAD). This was a pre-specified subgroup analysis of the INternational VErapamil SR-Trandolapril STudy (INVEST), which involved 22,576 clinically stable patients aged ≥ 50 years with hypertension and CAD randomized to either verapamil SR- or atenolol-based hypertension treatment strategies. The subgroup consisted of 117 patients undergoing 24-hour ambulatory monitoring at baseline and after 1 year of treatment. Hourly systolic and diastolic BP (SBP and DBP) decreased after 1 year for both verapamil SR- and atenolol-based treatment strategies compared with baseline (P<0.0001). Atenolol also decreased hourly HR (P<0.0001). Both treatment strategies decreased SBP variability (weighted standard deviation: P = 0.012 and 0.021, respectively). Compared with verapamil SR, atenolol also increased the prevalence of BP and HR nighttime dipping among prior non-dippers (BP: OR = 3.37; 95% CI: 1.26-8.97 P = 0.015; HR: OR = 4.06; 95% CI: 1.35-12.17; P = 0.012) and blunted HR morning surge (+2.8 vs. +4.5 beats/min/hr; P = 0.019). Both verapamil SR- and especially atenolol-based strategies resulted in favorable changes in ambulatory monitoring parameters that have been previously associated with increased adverse cardiovascular events.
url http://europepmc.org/articles/PMC4383326?pdf=render
work_keys_str_mv AT scottjdenardo effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT yangong effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT rhondamcooperdehoff effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT csabafarsang effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT matyaskeltai effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT laszloszirmai effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT franzhmesserli effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT anthonyabavry effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT eileenmhandberg effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT giuseppemancia effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
AT carljpepine effectsofverapamilsrandatenololon24hourbloodpressureandheartrateinhypertensionpatientswithcoronaryarterydiseaseaninternationalverapamilsrtrandolaprilambulatorymonitoringsubstudy
_version_ 1725355840059211776